Diagnostic tools and innovative therapies improve patient...(ced by the human as a reaction to the tu...),Health

Ten adenocarcinoma (AC) and two squamous cell carcinoma (SCC) cell lines were grown in standard conditions and compared to control. Gas-chromatography mass spectrometry was used to examine the chemical nature of the cancerous VOCs and an electrical nose device detected the difference between cancerous cells and the samples.

In the study, 350 to 400 different VOCs were identified in either tumor cells or controls. The analysis revealed 120 of the compounds appeared in all tumor and control cells with a high confidence interval (>89 percent). Of those 120 compounds, five were found to be present in all tumor cells but not in the control group, and three of those were present specifically in the exhaled breath of NSCLC patients. The three compounds that were present in exhaled breath were found in more than 90 percent of NSCLC patients.

Given this finding, researchers were able to conclude that VOCs transfer to the breath of patients via a metabolic pathway present in the tumor cells.

"Now that we have a better understanding of the origin of these compounds and have pinpointed their presence with a large degree of accuracy, we hope to use this information to develop a test that examines the exhaled breath of patients for early detection of lung cancer," says Nir Peled, M.D., lead author of the study, and Fulbright Scholar at the University of Colorado Cancer Center. "This research is a promising step toward an earlier, more accurate and cost-effective diagnosis for lung cancer patients."

Dr. Peled will present this study on Sunday, August, 2, 3:20 pm PT in Moscone West, Room 2016-2018, Level 2.

The compound iloprost, a form of pro
'/>"/>